Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors

Inclusion Criteria:

* Meets one of the following sets of criteria:

  * Dose-escalation group:

    * Histologically and/or cytologically confirmed solid malignancy
    * Metastatic or unresectable disease
    * Disease for which standard curative or palliative measures do not exist or are no longer effective
  * Expansion group:

    * Histologically and/or cytologically confirmed endometrial (endometrioid, uterine papillary serious carcinoma, or carcinosarcoma) or renal cell cancer
    * Metastatic or unresectable disease
    * Disease for which standard curative or palliative measures do not exist or are no longer effective
* Measurable or non-measurable disease

  * Measurable disease is defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan
* No known brain metastases
* ECOG performance status (PS) 0-1 (Karnofsky PS 70-100%)
* Life expectancy \> 12 weeks
* Leukocytes ≥ 3,000/mm\^3
* ANC ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Hemoglobin ≥ 90 g/L (or ≥ 9 g/dL)
* Total bilirubin normal
* AST/ALT ≤ 2.5 times upper limit of normal
* Serum creatinine normal OR creatine clearance ≥ 60 mL/min
* Fasting cholesterol ≤ 350 mg/dL (9.0 mmol/L)
* Fasting triglycerides ≤ 400 mg/dL (4.56 mmol/L)
* No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia or hypokalemia defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation

  * Note: it is acceptable to use corrected calcium when interpreting calcium levels
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use two effective forms of contraception (i.e., barrier contraception and one other method of contraception) for ≥ 4 weeks before, during, and for ≥ 12 months after completion of study therapy
* Able to swallow medication
* No malabsorption syndrome or other condition that would interfere with intestinal absorption
* No diarrhea ≥ grade 2 that is not under control with standard anti-diarrhea medications
* No uncontrolled concurrent illness including, but not limited to, any of the following:

  * Ongoing or active infection
  * Symptomatic congestive heart failure
  * Unstable anginal pectoris
  * Cardiac arrhythmia other than chronic, stable atrial fibrillation
  * Psychiatric illness or social situations that would limit compliance with study medications
* QTc ≤ 450 msec in males and a QTc ≤ 470 msec in females, as measured by ECG using Bazett formula
* No history of risk factors for QT interval prolongation including, but not limited to, a family or personal history of any of the following:

  * Long QT syndrome
  * Torsades de pointes
  * Recurrent syncope without known etiology
  * Sudden unexpected death
* No pre-existing significant pulmonary infiltrates of unknown origin
* No serologic positivity for hepatitis A, B, or C or history of liver disease or other forms of hepatitis or cirrhosis
* No HIV-positive patients on combination antiretroviral therapy
* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma-secretase inhibitor RO4929097 or temsirolimus
* Female patients may not donate ova during or after study treatment
* Male patients may not donate sperm during and for ≥ 12 months after completion of study treatment
* Patients may not donate blood during and for ≥ 12 months after completion of study treatment
* Any number of prior therapies allowed
* Recovered from side effects of previous systemic anticancer therapy to \< CTCAE grade 2 toxicity (except alopecia)
* Concurrent leuteinizing hormone-releasing hormone agonist allowed in patients with castration-resistant prostate cancer
* No prior gamma-secretase inhibitor or any inhibitor of the PI3K/Akt/mTOR pathway
* At least 4 weeks since prior radiotherapy or systemic therapy (6 weeks for carmustine, nitrosoureas, or mitomycin C)

  * Exceptions may be made for low-dose, non-myelosuppressive radiotherapy for symptomatic palliation
* No other concurrent investigational agents
* No concurrent medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin®)
* No concurrent medications that are strong inducers, inhibitors, or substrates of CYP3A4
* No antiarrhythmics or other concurrent medications with known potential to prolong QT interval
* No concurrent food that may interfere with the metabolism of gamma-secretase inhibitor RO4929097, including grapefruit or grapefruit juice
* No other concurrent anticancer agents or therapies